- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Aug 30, 2017 P1, N=24, Completed, These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. Active, not recruiting --> Completed
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment open: BIONICS Israel Trial (clinicaltrials.gov) - Nov 1, 2016 P=N/A, N=60, Recruiting, Trial primary completion date: Mar 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
New trial: BIONICS Israel Trial (clinicaltrials.gov) - Jul 15, 2016 P=N/A, N=60, Not yet recruiting,
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016 P2, N=216, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Trial primary completion date: Angiography Study of BioNIR Drug Eluting Stent System (NIREUS) (clinicaltrials.gov) - Dec 23, 2015 P2, N=300, Active, not recruiting, No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015
- |||||||||| Enrollment closed, Trial primary completion date: BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (clinicaltrials.gov) - Dec 4, 2015
P2, N=1906, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016
- |||||||||| Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 10, 2015 P1, N=16, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Sep 24, 2015 P1, N=24, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014 Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Monotherapy, Metastases: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (clinicaltrials.gov) - Nov 19, 2013 P1, N=21, Completed, Recruiting --> Active, not recruiting N=60 --> 21
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Monotherapy, Metastases: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (clinicaltrials.gov) - Nov 19, 2013 P1, N=21, Completed, N=60 --> 21 Active, not recruiting --> Completed
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Combination therapy, Monotherapy: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (clinicaltrials.gov) - Nov 4, 2013 P2, N=115, Completed, Active, not recruiting --> Completed N=352 --> 115
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Combination therapy, Monotherapy: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (clinicaltrials.gov) - Nov 4, 2013 P2, N=115, Completed, N=352 --> 115 Active, not recruiting --> Completed
- |||||||||| Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 2, 2013 P1, N=48, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial termination, Combination therapy, Metastases: A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) (clinicaltrials.gov) - May 1, 2013 P1, N=48, Terminated, Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.
- |||||||||| MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Combination therapy, Metastases: A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) (clinicaltrials.gov) - May 1, 2013 P1, N=48, Terminated, Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab. N=121 --> 48
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - Apr 30, 2013 P2, N=84, Active, not recruiting, N=121 --> 48 N=150 --> 84
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment closed: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - Apr 30, 2013 P2, N=84, Active, not recruiting, N=150 --> 84 Recruiting --> Active, not recruiting
- |||||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly
Trial termination, Metastases: Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) - Feb 21, 2013 P1, N=12, Terminated, Active, not recruiting --> Completed Recruiting --> Terminated; Determination to stop enrollment made due to funding
|